ANAGLIPTIN

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H25N7O2
Molecular Weight	383.4475
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N

InChI

InChIKey=LDXYBEHACFJIEL-HNNXBMFYSA-N

InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H25N7O2
Molecular Weight	383.4475
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.kowa-souyaku.co.jp/upload/item/24/35/7-wse_163.doc
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23337530

Anagliptin is a DPP-4 inhibitor developed for the treatment of type 2 diabetes mellitus. The drug was approved in Japan under the name Suiny and now it is being tested in the USA.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase IV 37 Target ID: CHEMBL284 Sources: http://www.kowa-souyaku.co.jp/upload/item/24/35/7-wse_163.doc	Inhibitor 8297		3.8 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: http://www.kowa-souyaku.co.jp/upload/item/24/35/7-wse_163.doc	Primary		Approved 8429	SUINY Approved Use It is usually used for the treatment of type 2 diabetes mellitus.

PubMed

Title	Date	PubMed
Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.	2013	24200798
Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.	2013 May	23075005
A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.	2015	25819061

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, take 1 tablet (100mg of anagliptin) at a time, twice a day, in the morning and in the evening. If the effect is insufficient, a dose may be increased up to 2 tablets (200mg) at a time, adequately monitoring the condition.

Route of Administration: Oral

In Vitro Use Guide

Rat aortic smooth muscle cells were incubated with 100 uM of anagliptin and its effect on cells prolifiration was studied. Anagliptin suppressed the proliferation by inhibiting ERK phosphorylation.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:59:16 GMT 2023` Edited by `admin` on `Fri Dec 15 17:59:16 GMT 2023`
Record UNII	K726J96838
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANAGLIPTIN

Official Name

English

Anagliptin [WHO-DD]

Common Name

English

ANAGLIPTIN [JAN]

Common Name

English

anagliptin [INN]

Common Name

English

N-(2-((2-((2S)-2-CYANOPYRROLIDIN-1-YL)-2-OXOETHYL)AMINO)-2-METHYLPROPYL)-2-METHYLPYRAZOLO(1,5-A)PYRIMIDINE-6-CARBOXAMIDE

Systematic Name

English

SK-0403

Code

English

SUINY

Brand Name

English

ANAGLIPTIN [MI]

Common Name

English

PYRAZOLO(1,5-A)PYRIMIDINE-6-CARBOXAMIDE, N-(2-((2-((2S)-2-CYANO-1-PYRROLIDINYL)-2-OXOETHYL)AMINO)-2-METHYLPROPYL)-2-METHYL-

Systematic Name

English

CWP-403

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C98086